Hamidi Sofiani Vahideh, Ebrahimian Shiadeh Arefeh, Tabarraei Alijan, Nikoo Hadi Razavi, Sadeghi Farzin, Kamrani Ghodsieh, Yahyapour Yousef, Moradi Abdolvahab
Department of Microbiology, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
Department of Medical Microbiology, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran.
J Int Med Res. 2024 Dec;52(12):3000605241302302. doi: 10.1177/03000605241302302.
This study aimed to explore the potential relationship between viral infections and gastrointestinal (GI) malignancies, focusing on the presence of KRAS G12D mutations. Specifically, we investigated the association of viral agents, including human papillomavirus (HPV) and Epstein-Barr virus (EBV), with KRAS G12D mutations in GI cancers to better understand their combined role in cancer development.
This cross-sectional study comprised 92 patients diagnosed with GI cancer and 100 healthy individuals in the control group. All samples were examined to detect the KRAS G12D gene mutation and the existence of HPV and EBV using real-time polymerase chain reaction assays.
HPV and EBV DNA were detected in 5.4% and 51.4% of gastric cancer samples and in 7.3% and 49.1% of colorectal cancer samples, respectively. Analysis of KRAS G12D in plasma samples revealed heterozygous mutations in 54% of patients with gastric cancer and 35% of patients with colorectal tumors. Among EBV-positive colorectal cancer samples, 1.8% were wild-type, while 47.2% exhibited heterozygous mutations. Among HPV-positive colorectal cancer patients, 1.8% exhibited wild-type KRAS, 5.4% had heterozygous mutations, and 3.2% had homozygous mutations.
This study detected a significant correlation between the presence of viral agents and KRAS G12D mutations.
本研究旨在探讨病毒感染与胃肠道（GI）恶性肿瘤之间的潜在关系，重点关注KRAS G12D突变的存在情况。具体而言，我们调查了包括人乳头瘤病毒（HPV）和爱泼斯坦-巴尔病毒（EBV）在内的病毒病原体与GI癌症中KRAS G12D突变的关联，以更好地了解它们在癌症发展中的联合作用。
这项横断面研究包括92例被诊断为GI癌症的患者和100名作为对照组的健康个体。所有样本均通过实时聚合酶链反应检测法进行检测，以检测KRAS G12D基因突变以及HPV和EBV的存在情况。
在胃癌样本中，分别有5.4%和51.4%检测到HPV和EBV DNA；在结直肠癌样本中，分别有7.3%和49.1%检测到HPV和EBV DNA。血浆样本中KRAS G12D的分析显示，54%的胃癌患者和35%的结直肠肿瘤患者存在杂合突变。在EBV阳性的结直肠癌样本中，1.8%为野生型，而47.2%表现为杂合突变。在HPV阳性的结直肠癌患者中，1.8%表现为KRAS野生型，5.4%有杂合突变，3.2%有纯合突变。
本研究检测到病毒病原体的存在与KRAS G12D突变之间存在显著相关性。
